CN105853781A - Maca composition and application thereof - Google Patents
Maca composition and application thereof Download PDFInfo
- Publication number
- CN105853781A CN105853781A CN201610209562.6A CN201610209562A CN105853781A CN 105853781 A CN105853781 A CN 105853781A CN 201610209562 A CN201610209562 A CN 201610209562A CN 105853781 A CN105853781 A CN 105853781A
- Authority
- CN
- China
- Prior art keywords
- composition
- agate card
- extract
- group
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition with an osteoporosis relieving effect. The composition is characterized by being prepared from the following active ingredients: a maca extract, highland barley, medical pipefish and dipsacus asperoids. In vivo and in vitro experiment researches prove that the composition generates synergetic effects and is capable of relieving bone mineral density reduction of an osteoporosis model animal, and is greatly superior individually used maca extract or other single ingredients; the maca aplicatin range is expanded; and a new choice is provided for further opening a maca health product.
Description
Technical field
The present invention relates to agate card composition, there is mitigating osteoporosis disease effect.
Background technology
Osteoporosis i.e. osteoporosis (osteoporosis), is one group of osteopathy causing of many reasons, bone group
Being woven with normal calcification, calcium salt and matrix are normal rates, are reduced to feature with unit volume inner bone tissues amount
Metabolic bone disease becomes.In most osteoporosises, the minimizing of bone tissue increases caused mainly due to bone absorption.
With skeleton pain, it is prone to fracture and is characterized.
Being presently used for treatment and stop the medicine of osteoporosis development to be divided into two big classes, the first kind is suppression bone
Absorb medicine, including calcium agent, vitamin D and activated vitamin D, calcitonin, diphosphate, estrogen and
Isoflavones；Equations of The Second Kind for promote bone patent medicine, including fluoride, anabolic steroids, parathyroid hormone and
Isoflavones.These medicines can stop bone information but the least to osteoplastic effect.
Agate card comes to South America, is a kind of traditional medicine and nutritious supplementary pharmaceutical, has multiple pharmacological effect.Such as,
Strengthening women and the fecundity of the male sex, improve sex dysfunction, the gentle solution menopause of pre-anti-osteoporosis is comprehensive
Disease etc..Estrin treatment is one of the maximally effective therapy for pre-anti-osteoporosis.Therefore, female
Hormone receptor there may be with the function of resisting osteoporosis of agate card and associates.Conventional research finds, the ethanol of agate card
Extract slightly improves serum estradiol level, and reduces follicle-stimulating hormone (FSH) level.Similar research finds, raises
Feed agate card dams and increase serum luteinizing principle level.These results show that agate card can pre-preventing bone rarefaction
Disease, its main mechanism is to be played a role by the unknown composition influence estrogen in plant.And it is nearest
Research finds, agate card extract N-benzyl palm can promote osteoblastic proliferation, differentiation and mineralising.Its
By BMP-2, core-binding factor, the expression of COL1 and ALP strengthens bon e formation.Additionally, agate card extracts
The effect of thing is better than N-benzyl palmitamide, shows that agate card anti-osteoporosis also has other active component,
The existence of such as Polyphenols, phytosterol and long-chain polyunsaturated fatty acid.These compositions can be by different
Mechanism, and their the next pre-preventing bone rarefaction of synergy.Can be it is clear that N-benzyl palmitamide be
The pre-anti-osteoporosis of agate card one of active component.But, up to now, about agate these effects of card
Most of active components and function thereof the most not yet can illustrate, and seriously hinder the exploitation of agate card and answering of agate card product
With.The secondary metabolite that the many that has agate card shows unique characteristics, such as agate card imidazole alkaloid etc..But, due to
Plant exists always and affects the alkaloid of its compound activity, seriously hinder the exploitation application of agate card product.
Taking the most merely agate card extract, its effect is the most notable.
The present invention provides a kind of novel agate card composition, and said composition can effectively treat osteoporosis.
Goal of the invention
The present invention provides a kind of novel agate card composition, and said composition can effectively treat osteoporosis.
Technical scheme
A kind of composition, it is characterised in that its main active is agate card extract, highland barley, sea otter, teasel root
Constitute.
Described a kind of composition, it is characterised in that count by weight, described agate card extract 1-100 part,
Highland barley 1-10 part, sea otter 1-20 part, teasel root 1-40 part, above-mentioned medicinal material or extract are crushed to powder, mixing
Obtain.
Described a kind of composition, it is characterised in that described agate card extract is prepared by following steps: take agate card
100 parts, pulverizing, 60 DEG C of the water adding 10 times of volumes soaks 10 hours, filters, and filtrate adds ethyl acetate extraction,
Ethyl acetate portion is concentrated into medicinal extract, to obtain final product.
The application in preparation treatment osteosporosis resistant medicament of the described composition.
Beneficial effect
In the present invention, the present composition produces synergistic function, and it can alleviate osteoporosis model animal
Bone density declines, and is significantly better than and is used alone agate card extract or other single components, widens agate card range of application,
One is provided to select for further open contact tone card health products.
Detailed description of the invention
Described agate card extract is prepared by following steps: take 100 parts of agate card, pulverizes, adds 10 times of volumes
60 DEG C of water soaks 10 hours, filters, repeat the above steps 3 times, collects filtrate, and filtrate adds 1 times of acetic acid second
Ester extracts three times, and ethyl acetate portion is concentrated into medicinal extract, to obtain final product.
The present invention relates to medicinal material purchased from Nanjing medicinal material company.
Embodiment 1
A kind of composition, it is characterised in that count by weight, described agate card extract 1 part, 1 part of highland barley,
Sea otter 1 part, teasel root 1 part, above-mentioned medicinal material or extract are crushed to powder, mix and get final product.
Embodiment 2
A kind of composition, it is characterised in that count by weight, described agate card extract 75 parts, highland barley 8
Part, sea otter 3 parts, teasel root 21 parts, above-mentioned medicinal material or extract are crushed to powder, mix and get final product.
Embodiment 3
A kind of composition, it is characterised in that count by weight, described agate card extract 100 parts, highland barley 10
Part, sea otter 20 parts, teasel root 40 parts, above-mentioned medicinal material or extract are crushed to powder, mix and get final product.
Embodiment 4
Composition is to vitro culture of human osteoblastic growth EC50.
Use MTT colorimetric method.By the human osteoblast cell of logarithmic growth, with 1.0 × 105Add 96 hole trainings
Supporting in plate, cultivate 24h, blank group adds the solvent of same volume；Positive group (female hormone, purchased from Sigma),
Experimental port (embodiment 1-3)；Agate card extract group；Highland barley group, sea otter group, teasel root group, any of the above addition
Variable concentrations medicine.Each dosage sets three multiple holes, and after cultivating 48h, every hole adds MTT, after effect 4h,
Add DMSO, hatch 30min, at ELIASA 620nm, measure absorbance A value, by formula skeletonization
Cell proliferation rate=(experimental group light absorption value-control group light absorption value)/control group light absorption value) × 100%.Calculate
The EC50 going out embodiment 1-3 is 12.15 μMs, 9.07 μMs, 11.37 μMs, positive group (female hormone) 8.25 μMs,
Agate card extract group 59.25 μMs, highland barley group 100.35mM, sea otter group 32.35 μMs, teasel root group 56.48 μMs.
There was no significant difference for present composition effect and positive group；But single give with other with agate card extract group
There were significant differences for medical instrument.
Embodiment 5
Impact on bone density
Take rat random packet: embodiment 1-3, positive controls, model group, agate card extract group, highland barley
Group, sea otter group, teasel root group, often group 10.Modeling and treatment rat with 10% chloraldurate with 3ml/100g
Row lumbar injection, after anesthesia is satisfied, is fixed on rat dorsal position on the mouse operating table of making in advance, in abdomen
Butt crack does longitudinal incision at center, is about 2cm, cuts skin and subcutaneous fascia, level cut off on the left of femoral nerve,
Excised 5mm near epimere, and made neural broken ends of fractured bone knotting, sewed up the incision.Rat is taken prone position again solid
On operating table, it is about 1cm's at greater trochanter of femur and between the afterbody with rear foreign side 45 ° of direction row
Otch, exposes sciatic nerve, is excised 5mm near near-end, and makees neural broken ends of fractured bone knotting, sews up the incision,
Common nursing was administered after 13 weeks.Treatment: model group is according to the dosage gavage physiological saline of 1ml/100g；Positive
Control group gavage 2.0ml diphosphate；Other organize gavage, successive administration 10 weeks.First use Dual X-ray bone
Density Measuring Instrument surveys bilateral femoral bmd.
Result: such as table 1.Compared with model group rats, embodiment 1-3 can conspicuousness be alleviated under rat bone density
Fall (P < 0.05).
The table 1 effect to rat bone density
* p < 0.05, * * p < 0.01 is compared with model group.
Claims (4)
1. a composition, it is characterised in that its main active is agate card extract, highland barley, sea otter, teasel root composition.
A kind of composition the most according to claim 1, it is characterised in that count by weight, described agate card extract 1-100 part, highland barley 1-10 part, sea otter 1-20 part, teasel root 1-40 part.
A kind of composition the most according to claim 1 and 2, it is characterised in that described agate card extract is prepared by following steps: take 100 parts of agate card, pulverizes, 60 DEG C of the water adding 10 times of volumes soaks 10 hours, filters, and filtrate adds ethyl acetate extraction, ethyl acetate portion is concentrated into medicinal extract, to obtain final product.
4. preparing, according to the composition of claim 1-3 any one, the application treated in osteosporosis resistant medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610209562.6A CN105853781A (en) | 2016-04-06 | 2016-04-06 | Maca composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610209562.6A CN105853781A (en) | 2016-04-06 | 2016-04-06 | Maca composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105853781A true CN105853781A (en) | 2016-08-17 |
Family
ID=56627172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610209562.6A Pending CN105853781A (en) | 2016-04-06 | 2016-04-06 | Maca composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853781A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103211972A (en) * | 2013-04-11 | 2013-07-24 | 天津天狮生物发展有限公司 | Kidney-tonifying composition and preparation method thereof |
| CN103275012A (en) * | 2013-06-08 | 2013-09-04 | 中国科学院过程工程研究所 | Preparation method and application of Maca alkaloid |
| CN103463123A (en) * | 2013-09-30 | 2013-12-25 | 云南省农业科学院药用植物研究所 | Method for extracting effective constituents from maca |
| CN105124583A (en) * | 2015-09-11 | 2015-12-09 | 苏州济天下生物科技有限公司 | Health-care food capable of enhancing bone mineral density and preparation method thereof |
-
2016
- 2016-04-06 CN CN201610209562.6A patent/CN105853781A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103211972A (en) * | 2013-04-11 | 2013-07-24 | 天津天狮生物发展有限公司 | Kidney-tonifying composition and preparation method thereof |
| CN103275012A (en) * | 2013-06-08 | 2013-09-04 | 中国科学院过程工程研究所 | Preparation method and application of Maca alkaloid |
| CN103463123A (en) * | 2013-09-30 | 2013-12-25 | 云南省农业科学院药用植物研究所 | Method for extracting effective constituents from maca |
| CN105124583A (en) * | 2015-09-11 | 2015-12-09 | 苏州济天下生物科技有限公司 | Health-care food capable of enhancing bone mineral density and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 颜德馨等: "《中华养生大全》", 31 December 2001, 上海：上海科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69008476T2 (en) | Pharmaceutical composition for the treatment of osteoporosis. | |
| CN109316528A (en) | A kind of drug and preparation method thereof for treating male erectile dysfunction | |
| CN106880839A (en) | A kind of deer osteocomma and preparation method thereof | |
| WO2017005159A1 (en) | Natural pharmaceutical composition for treating osteoporotic fracture and/or osteoarthritis and use thereof | |
| CN102512574B (en) | Traditional Chinese medicine composition for treating animal rickets, its preparation method and its application | |
| CN105853781A (en) | Maca composition and application thereof | |
| CN101214276A (en) | Plant medicine for treating BPH with cassia twig (or cinnamon) as raw material | |
| CN107802648A (en) | A kind of concocting method of the natural cod-liver oil of anti-curing osteoporosis | |
| US20200276255A1 (en) | Composition for preventing, improving or treating female menopausal disease | |
| AU2007205284A1 (en) | Herbal compositions for treating or preventing climacteric symptoms and use thereof | |
| CN105748552A (en) | Maca composition and application thereof | |
| CN1332679C (en) | Traditional Chinese medicine composition for treating osteoporosis, and its prepn. method | |
| JP2010100547A (en) | Agent for reducing or preventing side effect of hormone therapy and agent for suppressing or preventing recurrence of dysmenorrhea after hormone therapy | |
| KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
| CN101297860A (en) | Chinese medicinal composition for preventing and controlling heat stress and heatstroke of birds | |
| CN101002808A (en) | Medical use of bidentate achyanthes total sterone | |
| CN104644988A (en) | Traditional Chinese medicine preparation for treating impotence and production process | |
| US11058737B2 (en) | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females | |
| RU2601112C1 (en) | Method for recovery of cartilaginous and bone tissue in osteoporosis | |
| WO2022104712A1 (en) | Compound composition having effect of promoting bone health, preparation method therefor and application thereof | |
| CN112704680B (en) | Composition for preventing and/or treating organ fibrosis and application and preparation thereof | |
| Magdy Mohamady et al. | Effect of fenugreek seed extract (Trigonella foenum-graecum) in letrozole induced polycystic ovary syndrome in female albino rat | |
| CN102397510B (en) | Compound propolis composition for treating chicken Marek's disease and preparation method thereof | |
| CN111728985B (en) | A composition containing oviductus Ranae as main ingredient and its application | |
| CN112439010B (en) | Traditional Chinese medicine composition for tonifying qi, tonifying kidney and strengthening and shrinking and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160817 |